Ecromeximab
From Self-sufficiency
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | GD3 ganglioside |
| Identifiers | |
| CAS Number | 292819-64-8 |
| ATC code | none |
| Chemical data | |
| Molar mass | 145,255 Daltons |
Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2]
This drug was developed by Kyowa Hakko Kogyo Co., Ltd.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab, American Medical Association.
- ↑ ClinicalTrials.gov NCT00679289 Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Pages with broken file links
- Monoclonal antibody stubs
